Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Akela Pharma, a drug development company, has achieved the third milestone in a series of three Fentanyl Taifun Phase III study related milestones to be paid by Janssen Pharmaceutica.
Subscribe to our email newsletter
The milestone payment of E2.5 million was triggered by enrolling the seventh patient in the multinational Fentanyl Taifun Phase III program in late December 2008.
Enrollment is ongoing in a number of European study centers and further sites will be initiated during this quarter in both Europe and India.
Janssen Pharmaceutica is the licensee for the product in Europe, Canada, Middle East and Africa.